Endo Pharmaceuticals Holdings Inc. (ENDP)
Q1 2012 Earnings Call
May 1, 2012 9:00 AM ET
Blaine Davis – Head, IR
David Holveck – President and CEO
Julie McHugh – EVP and COO
Alan Levin – EVP and CFO
Ivan Gergel – EVP, Research and Development
Marc Goodman – UBS
John Boris – Citi
Gregg Gilbert – Bank of America/Merrill Lynch
Ken Cacciatore – Cowen & Company
Corey Davis – Jefferies
Traver Davis – Piper Jaffray
Annabel Samimy – Stifel Nicolaus
Gary Nachman – Susquehanna
Michael Faerm – Credit Suisse
Greg Waterman – Goldman Sachs
David Buck – Buckingham Research
Jimmy Stuttman – JP Morgan
Michael Schmidt – Leerink
Irina Rivkind – Cantor Fitzgerald
Good day, ladies and gentlemen, and welcome to the Q1 2012 Endo Pharmaceuticals Earnings Conference Call.
I’d now like to turn the call over to Mr. Blaine Davis, Senior Vice President of Corporate Affairs. Please go ahead sir.
Good morning everyone. Thanks for joining us. With me on this morning’s call are Dave Holveck, President and CEO; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer; and Alan Levin, Chief Financial Officer. After our prepared remarks, we’ll open the call to your questions.
I’d like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and subject to risks, change and uncertainties described in today’s press release and in our filings with the SEC.